Regentis Biomaterials grants stock options to director

Regentis Biomaterials director Ben-Elazar Pini received two employee stock option grants covering 8,313 and 24,826 ordinary shares.

Rhea-AI Filing Summary

Regentis Biomaterials director Ben-Elazar Pini received two employee stock option grants covering 8,313 and 24,826 ordinary shares. The options have exercise prices of 0.0030 and 2.1600 per share; one grant is fully vested, while the other vests quarterly through June 4, 2029 under the 2024 Share Option Plan.

Filing Explained

The July 9, 2026 approval made two option grants effective for reporting, creating potential future share purchases rather than reporting shares issued.

A Form 4 reports an insider transaction within two business days; this July 13, 2026 filing identifies a director and reports two option grants after shareholder approval on July 9, 2026. The grants are recorded as derivative rights to acquire ordinary shares, so the filing reports an award of options rather than an option exercise or ordinary-share issuance.

One option covers 24,826 ordinary shares at an exercise price of $2.16, and the other covers 8,313 ordinary shares at $0.003. The 24,826-share option begins vesting on September 4, 2026 in quarterly installments through June 4, 2029, while the 8,313-share option is fully vested as of the filing.

The 24,826-share option remains subject to the reporting person's continuous employment through each applicable vesting date, and the filing does not disclose a Rule 10b5-1 trading plan for these grants.

Sources and calculations

• Regentis Biomaterials Ltd. Form 4 (2026-07-13)
• Form 4 purpose and codes (2026-07-12)

Insider Trade Summary

Grant/Award: 33,139 shares

Grant/Award 2 txns

Insider Ben-Elazar Pini

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F1, F2, F5	24,826	$0.00	$0.00
Grant/Award	Employee Stock Option (Right to Buy) F3, F4, F5	8,313	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 33,139 contracts (Direct)

Footnotes (5)

1. F1. This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
2. F2. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029.
3. F3. This option grant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
4. F4. This option grant is fully vested as of this date.
5. F5. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.

Key Figures

Options granted (first grant): 8,313 shares Exercise price (first grant): 0.0030 per share Options granted (second grant): 24,826 shares +1 more

4 metrics

Options granted (first grant) 8,313 shares Employee stock options granted to director Ben-Elazar Pini, fully vested as of July 9, 2026

Exercise price (first grant) 0.0030 per share Conversion or exercise price for 8,313 employee stock options over ordinary shares

Options granted (second grant) 24,826 shares Employee stock options vesting in 1/12 increments quarterly until June 4, 2029

Exercise price (second grant) 2.1600 per share Conversion or exercise price for 24,826 employee stock options over ordinary shares

Key Terms

Employee Stock Option (Right to Buy), Section 102 of the Israeli Tax Ordinance, 2024 Share Option Plan

3 terms

Employee Stock Option (Right to Buy) financial

"security title "Employee Stock Option (Right to Buy)" granted to the director"

Section 102 of the Israeli Tax Ordinance regulatory

"tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee"

2024 Share Option Plan financial

"in connection with the Issuer's 2024 Share Option Plan must be registered"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ben-Elazar Pini report for Regentis Biomaterials (RGNT)?

Ben-Elazar Pini reported receiving two employee stock option grants at Regentis Biomaterials. These derivative awards cover underlying 8,313 and 24,826 ordinary shares, reflecting equity-based compensation rather than any open-market share purchases or sales.

How many stock options were granted to Ben-Elazar Pini at RGNT and at what exercise prices?

Pini was granted 8,313 options with an exercise price of 0.0030 per share and 24,826 options with an exercise price of 2.1600 per share. Each option corresponds to one underlying ordinary share of Regentis Biomaterials.

What is the vesting schedule for the 24,826 Regentis Biomaterials (RGNT) options?

The 24,826 options vest on a quarterly schedule. One-twelfth (1/12) vests on September 4, 2026, with an additional one-twelfth vesting on the last day of each subsequent three-month period until full vesting on June 4, 2029.

Are any of Ben-Elazar Pini’s new Regentis Biomaterials (RGNT) options already fully vested?

Yes. The grant covering 8,313 underlying ordinary shares is described as fully vested as of the transaction date. This means those options are immediately exercisable, subject to their stated exercise price and expiration date in 2036.

How does Section 102 of the Israeli Tax Ordinance affect these RGNT option grants?

The filing notes that to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the 2024 Share Option Plan must be registered in the name of a trustee, a structural requirement for these employee equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben-Elazar Pini

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYHEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)(5)	$2.16	07/09/2026		A		24,826		09/04/2026	06/04/2036	Ordinary Shares	24,826	$0	24,826	D
Employee Stock Option (Right to Buy)(3)(4)(5)	$0.003	07/09/2026		A		8,313		02/23/2026	02/23/2036	Ordinary Shares	8,313	$0	8,313	D

Explanation of Responses:

1. This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026.

2. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029.

3. This option grant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.

4. This option grant is fully vested as of this date.

5. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.

	/s/ Pini Ben-Elazar	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)